PDCD1 and non-small cell lung carcinoma: ICIs, such as anti-programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) antibodies, were initially approved as second-line monotherapy in metastatic NSCLC, showing a survival benefit compared to docetaxel monotherapy [2, 3].